- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Six countries and three regional programs are being invited as early applicants to participate in the full process of the new funding model, from submitting a concept note to creating a new grant. The countries – Zimbabwe, El Salvador, Myanmar, the Democratic Republic of the Congo, Kazakhstan and the Philippines – will be able to access a total of US$364 million in new funding in the transition period. They can also apply for additional funds that incentivize ambitious and high impact investments and co-financing.
Principles of the new funding model
• Greater alignment with country schedules, context, and priorities
• Focus on countries with the highest disease burden and lowest ability to pay, while keeping the portfolio global
• Simplicity for both implementers and the Global Fund
• Predictability of process and financing levels
• Ability to elicit full expressions of demand and reward ambition
A transition to the new funding model is underway. Access to funding in the transition phase is by invitation, and special consideration will be given to countries in a position to achieve rapid impact, those at risk of service interruptions, and those currently receiving less than they would under the new funding model’s allocation principles. There is diversity across regions and diseases and types of applicants, so that elements of the new funding model can be tested and refined.
The HIV Investment Framework (IF) is a model for HIV and AIDS investment and prioritisation for maximum impact. The IF advocates for a short-term increase in HIV funding in order to reduce funding requirements over the long term. IF is aligned to the investment thinking approach to resourcing of the HIV response. This means treating resources for the HIV response as investments that will deliver returns, rather than as expenses that will always have gaps demanding to be filled.
HIV investment cases provide an important vehicle for countries to deliver strategic, rights-based, sustainable responses to HIV. The process of developing investment cases provides countries with new opportunities to explore options for innovative funding and service delivery, to identify specific steps to enhance equity and inclusiveness for key populations, to use available evidence to understand better the health and economic benefits of timely, rights-based, smart HIV investments and to eliminate inefficiency in HIV programmes.
This paper provides an overview of the challenges of financing health care in the region, where many countries are striving to achieve universal health coverage. It examines the contributions of the public and private sectors, and considers the future of external development aid. The paper concludes with reflections on the implications for development partners, discussing how policy issues can be tackled, how aid modalities should develop and where donor assistance should be focused to maximise impact.
To provide some perspective on the geographic presence of global health donors and to help stakeholders begin to answer some of the above questions, the Kaiser Family Foundation is undertaking a series of analyses to describe the global health “donor landscape.” Using three years of data from the Organisation for Economic Co-operation and Development (OECD), we map the geographic landscape of global health donor assistance, looking both at donor presence and magnitude of donor assistance by issue area, region, and country. The effort is intended to shed new light on donor presence within and across recipient countries, and to produce a set of figures and tools that stakeholders can use in both donor and recipient countries.
NASA team always aims to collect expenditure data from all actors of the response. These organizations – actors of the HIV response – are playing different roles in different transactions, either financial or in-kind. The organization acts as a Financing Source when it makes money available for the country’s HIV response. It transfers funds to the other organizations who decide what should be implemented and who will be implementing. This role is a role of a Financing.
This summary report is intended to provide the pricing data of key ARVs to governments, nongovernmental organizations, donors, international organizations, academia and individuals or institutions directly involved or interested in the procurement of ARVs in resource-poor settings.
HIV and AIDS are among health issues prioritized in the Millenium Development Goals (MDGs) and require considerable attention from various stakeholders. The Government of Indonesia, along with international partners has been working hard in suppressing the spread of AIDS in the country through various programs. However, more challenges remain, and despite considerable amount of money spent in resources to combat HIV and AIDS in Indonesia, the rate of new cases of HIV continue to persist.
Keywords: NASA, expenditures, spending, prevention, treatment, vulnerable